Brief: Maxigen Biotech gets marketing approval for Foramic Bone Graft Substitutes from CFDA
29/09/2016 12:06
Sept 29 (Reuters) - Maxigen Biotech 1783.TW :
* Says it got marketing approval for its product Foramic
Bone Graft Substitutes from CFDA (China Food and Drug
Administration) on Sep. 29
Source text in Chinese: https://goo.gl/wiFdgh
Further company coverage: 1783.TW
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com;)(+86 010
62674724;)(Reuters
Messaging:)(shuai.liu.reuters.com@reuters.net))
Recent news on Maxigen Biotech
See all newsInsurer MBIA hits over 6-month high after KBW upgrades to 'outperform'
Brief: Maxigen Biotech to pay dividend on Aug. 24
Brief: Maxigen Biotech product Formaderm Charming Dermal Filler Injection receives TFDA approval for marketing
Brief: Maxigen Biotech announces no dividend payment for 2016
Brief: Maxigen Biotech gets marketing approval for ArtiBest Intra-articular Injection from TFDA